John Cullity
Torreya Insights is a professional and data services company that integrates advice, transaction preparation and database analysis for life science companies. We primarily service business development and financing professionals in the biotech and pharmaceutical industries.
We are a sister company to Torreya Partners, a leading life sciences boutique M&A and financial advisory firm based in New York, which since its inception in 2007 has completed over 100 transactions in life sciences (www.torreyapartners.com). We work closely with Torreya Partners to seamlessly integrate the services that we provide to our clients.
Our engagements usually center around assisting companies in business development transactions, including capital raise, valuation, as well as locating suitable assets for acquisition or potential partners for further asset development.
We also provide access to AvaRx (which soft launched in January 2014) is a searchable dynamic database of over 2,000 licensing opportunities.
Follow us at @TorreyaInsights for updates.
Licensing / M&A Opportunity Identification, Research and Data Services, AvaRx – Licensing Opportunity Database, BioPharma CRM & Contact Solutions, Licensing Dynamics, Financing Dynamics
Torreya Insights
CBO
Mr Christopher Cummings
Life Science Nation (LSN) was founded by Dennis Ford, CEO, in 2012 to bring a better sales and marketing awareness to the life science community. LSN’s goal is to educate scientists in the basic skills required to brand, message, and market their companies.
Before LSN, Dennis was the CEO of a company that pioneered a system for uncovering global institutional investors and gauging their appetite regarding investing in hedge funds, private equity funds, and venture capital (VC) funds. The methodology used to capture and curate this valuable data was developed in part by a research team that would cold call and canvass these investors. The team would conduct a one-on-one interview with each investor that uncovered any current investment mandates they had. This allowed them to identify exactly where the capital was and specifically who had the mandate to deploy it.
After working with fundraisers in the alternative finance space for six years, Dennis wanted to bring his expertise to the life sciences and channel this fundraising experience toward the goal of moving science forward. Dennis knew from his experience in the alternatives field that many institutional investors and family offices were starting to withdraw capital from funds due to a decade of sub-par returns, initiating a trend of direct investment. This dovetailed with an accelerating trend of philanthropic investment and a desire among many investors to eradicate diseases affecting their family, friends or other groups that they have an affinity towards.
Identifying who has capital and is a fit for your company is the conundrum of the life science arena. The life science industry is poised at the entryway of a new golden age. The one factor holding back the life science explosion is lack of capital. Dennis’s vision led him to believe that LSN could expedite the capital-raising problem by identifying active life science investors seeking emerging biotech and medtech companies and creating in-depth profiles that detail their specific preferences. This would allow scientist-entrepreneurs to identify investors based on fit for their stage and sector, thus greatly enhancing the results of their outbound fundraising campaigns.
Dennis sought to create a match.com-like sourcing platform for the life sciences. He knew that he needed not only current, accurate, and actionable information on both of the constituent groups who would use the platform, but also a home for the data he had started to gather on early stage life science investors.
Life Science Nation
Business Development
Christian Curel
Infectious Diseases - Vaccines
Ivd / Diagnostics
Your innovative solution
i2a is a company working on microbiology automation. The objective is to offer a global solution from the arrival of samples to the final results. i2a manufactures and sells pre-analytical device, automatic incubator automatic reader-incubator, software, reagents and consumables. The current total bacteriology automation proposed by i2a strengthens quality, optimizes sample flow, enhances flexibility and reduces costs.
Each clinical microbiology laboratory is unique and its organization may vary, but they all have seen a 10
Market segment 1: Hospital Clinical Lab of Microbiology Market segment 2: Reference Lab of Microbiology Market segment 3: Small and Medium Private Lab of Microbiology
Advantage 1: Strenghten quality Advantage 2: Enhance flexibility Advantage 3: Optimize sample flow Advantage 4: Reduce costs
i2a
CEO & Founder
Armelle CUVILLIER
B Cell Design promotes a new approach of mucosal immunotherapies. The innovation is based on a technology platform to generate a large number of drug and vaccine candidates in infectious diseases and oncology.
The preferential tropism of class A isotype for mucosal compartments is the key in treatment of infectious diseases and mucosal cancers (gut, lung) strategies. Its high resistance (under its secretory form) through the entire digestive tracts, allow an oral administration of anti-cancer immunotherapy. B CELL DESIGN develops a new concept of therapeutic IgA and secretory IgA for anti-colorectal cancer therapy and medical imaging of early-stage metastasis. To target AIDS, B Cell Design develops an alternative vaccine approach for a mucosal induction of a neutralizing response, at the gate of entrance of the virus.
Based on an innovative platform of humanized transgenic mice models, B CELL DESIGN offers a complete panel of specific monoclonal antibodies, hIgG1, hIgA1, hIgA2, SIgA1, hIgM and hIgE. The main issue in the diagnostic industry is to solve the problem of supply in specific human sera, as positive controls and calibrators for their diagnostic kits. Plus, for some diseases, patients developed a combined immune response, requiring testing various isotypes. B CELL DESIGN offers secure solutions to overcome supplying restraints. Working with monoclonal antibodies offers a perfect reproducibility of antibodies affinity, allows keeping quality track of all components of the kit, and ensures a complete safety for users because of a non-human cellular manufacturing system.
OBJECTIVES :
B CELL DESIGN is seeking for partners to pursue the development of our drug candidates and to initiate new projects based on our technological platform.
